Many people using GLP-1 agonists notice that they feel full more quickly, stay full for longer and reduce their overall food intake without following rigid diets
These metabolites are involved in various metabolic pathways, including glucose metabolism, glutamine metabolism, lactate metabolism, pyruvate metabolism, ketone body and fatty acid metabolism, amino acid metabolism, etc [1]
doi: 10.1002/jnr.21483 16 BlackC.MillerB
Both are valid
Obesity is linked to increased risk of HF incidence, particularly HFpEF ( 3.5 Effects on arrythmia GLP-1 RAs were associated with a significant reduction in all-cause mortality and CV mortality, and did not increase the risk of sudden cardiac death, atrial arrythmias, or ventricular arrhythmias in T2DM patients ( 3.6 GLP-1 RAs in clinical practice The cardioprotective properties of GLP-1 RAs seem to be mediated through CV risk factors modification